Loading...
Whether prolonged treatment reduces persistent Lyme disease symptoms is controversial. To resolve this issue, investigators in the Netherlands conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 280 Lyme disease patients with persistent musculoskeletal pain, arthritis, arthralgia, neuralgia, sensory disturbances, dysesthesia, neuropsychological disorders, or cognitive disorders, with or without persistent fatigue. The median duration of symptoms was longer than 2 years.
Patients received initial intravenous ceftriaxone for 2 weeks followed by one of three oral regimens: doxycycline (86 patients), clarithromycin plus hydroxychloroquine (96 patients), or placebo (98 patients) for 12 weeks. The primary outcome …